Literature DB >> 35190669

Retina: a unique subspecialty in the biosimilar landscape.

Ashish Sharma1, Nilesh Kumar2,3, Nikulaa Parachuri2,4, Carl D Regillo5, Francesco Bandello6, Baruch D Kuppermann7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35190669      PMCID： PMC9151666          DOI： 10.1038/s41433-022-01984-w

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  12 in total

1.  Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Sonali Singh; Francesco Bandello; Carl D Regillo; David Boyer; Quan Dong Nguyen
Journal:  Ocul Immunol Inflamm       Date:  2021-05-20       Impact factor: 3.070

2.  Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect.

Authors:  Ashish Sharma; Nilesh Kumar; Francesco Bandello; Anat Loewenstein; Baruch D Kuppermann
Journal:  Eye (Lond)       Date:  2019-11-29       Impact factor: 3.775

Review 3.  Biosimilars for Retinal Diseases: An Update.

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal:  Am J Ophthalmol       Date:  2020-12-09       Impact factor: 5.258

4.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Authors:  Pravin U Dugel; Adrian Koh; Yuichiro Ogura; Glenn J Jaffe; Ursula Schmidt-Erfurth; David M Brown; Andre V Gomes; James Warburton; Andreas Weichselberger; Frank G Holz
Journal:  Ophthalmology       Date:  2019-04-12       Impact factor: 12.079

5.  Ophthalmic biosimilars: Lessons from India.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Bandello Francesco; Anat Lowenstein
Journal:  Indian J Ophthalmol       Date:  2019-08       Impact factor: 1.848

6.  Medical specialists' attitudes to prescribing biosimilars.

Authors:  Amy Hemmington; Nicola Dalbeth; Paul Jarrett; Alan G Fraser; Reuben Broom; Peter Browett; Keith J Petrie
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-02-24       Impact factor: 2.890

7.  Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial.

Authors:  Perwez Khan; Lubna Khan; Prosenjit Mondal
Journal:  Indian J Ophthalmol       Date:  2016-09       Impact factor: 1.848

8.  Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.

Authors:  Robert P Finger; Vincent Daien; Bora M Eldem; James S Talks; Jean-Francois Korobelnik; Paul Mitchell; Taiji Sakamoto; Tien Yin Wong; Krystallia Pantiri; Joao Carrasco
Journal:  BMC Ophthalmol       Date:  2020-07-17       Impact factor: 2.209

9.  Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.

Authors:  Jay U Sheth; Michael W Stewart; Manoj Khatri; Shashank R Gupta; Shobhit Chawla; Anand Rajendran; Raja Narayanan
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

10.  Using intravitreal bevacizumab (Avastin®) - Indian Scenario.

Authors:  Atul Kumar; Raghav Ravani
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848
View more
  1 in total

1.  Effects of Flow Hydrodynamics and Eye Movements on Intraocular Drug Clearance.

Authors:  Angeliki Velentza-Almpani; Nkiruka Ibeanu; Tianyang Liu; Christopher Redhead; Peng Tee Khaw; Steve Brocchini; Sahar Awwad; Yann Bouremel
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.